Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Abstract Background Hemodialysis patients are more likely to be severely affected if infected by COVID-19. Contributing factors include chronic kidney disease, old age, hypertension, type 2 diabetes, heart disease, and cerebrovascular disease. Therefore, action against COVID-19 for hemodialysis pati...
Main Authors: | Ryoichi Miyazaki, Kyoko Miyagi, Misaki Yoshida, Yasunori Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-02-01
|
Series: | Renal Replacement Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41100-022-00452-1 |
Similar Items
-
Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-07-01) -
Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
by: Timna Agur, et al.
Published: (2022-03-01) -
Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2022-02-01) -
Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01) -
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
by: Erez Bar-Haim, et al.
Published: (2022-05-01)